Skip to main
CLGN

CLGN Stock Forecast & Price Target

CLGN Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CollPlant Biotechnologies Ltd demonstrates a robust growth trajectory fueled by its innovative rhCollagen-based products, particularly the Collink.3D bioink, which has shown superior properties in tissue engineering compared to traditional options. The operational launch of a U.S.-based logistics center is anticipated to enhance sales of BioInk and rhCollagen, especially as adoption increases among research institutions and customers in the tissue-engineering sector. With its strategic partnerships and ongoing advancements in regulatory approvals for products like the photocurable dermal filler, the company is poised for significant market adaptability and revenue growth within the regenerative and aesthetic medicine fields.

Bears say

CollPlant Biotechnologies Ltd's recent $2.0 million registered direct financing, priced at $1.25 per share, indicates sustained equity pressure and highlights the company's difficulties in capital formation amidst a challenging market environment. The decision to lower expectations for products such as Dermal Fillers and BioInk, alongside the removal of Breast Implants from financial models, reflects a weakening outlook for key revenue-generating segments. This combination of factors has raised concerns about investor confidence, potentially exacerbating a downward spiral in valuation.

CLGN has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CollPlant Biotechnologies Ltd - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CollPlant Biotechnologies Ltd - ADR (CLGN) Forecast

Analysts have given CLGN a Strong Buy based on their latest research and market trends.

According to 2 analysts, CLGN has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CollPlant Biotechnologies Ltd - ADR (CLGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.